Literature DB >> 15504965

Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study.

Naveed Sattar1, Olga Scherbakova, Ian Ford, Denis St J O'Reilly, Adrian Stanley, Ewan Forrest, Peter W Macfarlane, Chris J Packard, Stuart M Cobbe, James Shepherd.   

Abstract

We examined the association of serum alanine aminotransferase (ALT) with features of the metabolic syndrome and whether it predicted incident diabetes independently of routinely measured factors in 5,974 men in the West of Scotland Coronary Prevention Study. A total of 139 men developed new diabetes over 4.9 years of follow-up. ALT, but not aspartate aminotransferase, levels increased progressively with the increasing number of metabolic syndrome abnormalities from (means +/- SD) 20.9 +/- 7.6 units/l in those with none to 28.1 +/- 10.1 units/l in those with four or more (P < 0.001). In a univariate analysis, men with ALT in the top quartile (ALT >/=29 units/l) had an elevated risk for diabetes (hazard ratio 3.38 [95% CI 1.99-5.73]) versus those in the bottom quartile (<17 units/l). ALT remained a predictor with adjustment for age, BMI, triglycerides, HDL cholesterol, systolic blood pressure, glucose, and alcohol intake (2.04 [1.16-3.58] for the fourth versus first quartile). In stepwise regression, incorporating ALT and C-reactive protein (CRP) together with metabolic syndrome criteria, elevated ALT (>/=29 units/l), and CRP (>/=3 mg/l) predicted incident diabetes, but low HDL cholesterol and hypertension did not. Thus, elevated ALT levels within the "normal" range predict incident diabetes. The simplicity of ALT measurement and its availability in routine clinical practice suggest that this enzyme activity could be included in future diabetes prediction algorithms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15504965     DOI: 10.2337/diabetes.53.11.2855

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  87 in total

1.  The relation between C reactive protein and age related macular degeneration in the Cardiovascular Health Study.

Authors:  G McGwin; T A Hall; A Xie; C Owsley
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

2.  Liver enzymes, type 2 diabetes, and metabolic syndrome in middle-aged, urban Chinese men.

Authors:  Raquel Villegas; Yong-Bing Xiang; Tom Elasy; Qiuyin Cai; Wanghong Xu; Honglan Li; Sergio Fazio; Macrae F Linton; David Raiford; Wei Zheng; Xiao Ou Shu
Journal:  Metab Syndr Relat Disord       Date:  2011-04-15       Impact factor: 1.894

3.  Associations between gamma-glutamyl transferase, metabolic abnormalities and inflammation in healthy subjects from a population-based cohort: a possible implication for oxidative stress.

Authors:  Simona Bo; Roberto Gambino; Marilena Durazzo; Sabrina Guidi; Elisa Tiozzo; Federica Ghione; Luigi Gentile; Maurizio Cassader; Gian Franco Pagano
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

Review 4.  Nonalcoholic fatty liver disease and cardiovascular disease risk.

Authors:  Roger K Schindhelm; Michaela Diamant; Robert J Heine
Journal:  Curr Diab Rep       Date:  2007-06       Impact factor: 4.810

5.  Impact of weight-loss surgery and diabetes status on serum ALT levels.

Authors:  Dimitrios Xourafas; Ali Ardestani; Stanley W Ashley; Ali Tavakkoli
Journal:  Obes Surg       Date:  2012-10       Impact factor: 4.129

Review 6.  Fatty liver in childhood.

Authors:  Yesim Ozturk; Ozlem Bekem Soylu
Journal:  World J Hepatol       Date:  2014-01-27

Review 7.  Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities?

Authors:  N Sattar; S G Wannamethee; N G Forouhi
Journal:  Diabetologia       Date:  2008-04-08       Impact factor: 10.122

8.  Probable NAFLD, by ALT levels, and diabetes among Filipino-American women.

Authors:  Charlene A Wong; Maria Rosario G Araneta; Elizabeth Barrett-Connor; John Alcaraz; Donna Castañeda; Carol Macera
Journal:  Diabetes Res Clin Pract       Date:  2007-08-30       Impact factor: 5.602

Review 9.  Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Authors:  Romina Lomonaco; Nishanth E Sunny; Fernando Bril; Kenneth Cusi
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

Review 10.  The metabolic syndrome and nonalcoholic fatty liver disease in children.

Authors:  Shikha S Sundaram; Phil Zeitler; Kristen Nadeau
Journal:  Curr Opin Pediatr       Date:  2009-08       Impact factor: 2.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.